These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27604319)

  • 1. Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding.
    Panico M; Bouché L; Binet D; O'Connor MJ; Rahman D; Pang PC; Canis K; North SJ; Desrosiers RC; Chertova E; Keele BF; Bess JW; Lifson JD; Haslam SM; Dell A; Morris HR
    Sci Rep; 2016 Sep; 6():32956. PubMed ID: 27604319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
    Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
    Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.
    Zhou T; Zheng A; Baxa U; Chuang GY; Georgiev IS; Kong R; O'Dell S; Shahzad-Ul-Hussan S; Shen CH; Tsybovsky Y; Bailer RT; Gift SK; Louder MK; McKee K; Rawi R; Stevenson CH; Stewart-Jones GBE; Taft JD; Waltari E; Yang Y; Zhang B; Shivatare SS; Shivatare VS; Lee CD; Wu CY; ; Mullikin JC; Bewley CA; Burton DR; Polonis VR; Shapiro L; Wong CH; Mascola JR; Kwong PD; Wu X
    Immunity; 2018 Mar; 48(3):500-513.e6. PubMed ID: 29548671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
    Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
    Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.
    Pritchard LK; Spencer DI; Royle L; Vasiljevic S; Krumm SA; Doores KJ; Crispin M
    J Virol; 2015 Jul; 89(13):6952-9. PubMed ID: 25878100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.
    Drummer HE; Hill MK; Maerz AL; Wood S; Ramsland PA; Mak J; Poumbourios P
    PLoS Pathog; 2013; 9(4):e1003218. PubMed ID: 23592978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.
    Doores KJ; Bonomelli C; Harvey DJ; Vasiljevic S; Dwek RA; Burton DR; Crispin M; Scanlan CN
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13800-5. PubMed ID: 20643940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
    Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
    J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.
    Pritchard LK; Harvey DJ; Bonomelli C; Crispin M; Doores KJ
    J Virol; 2015 Sep; 89(17):8932-44. PubMed ID: 26085151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
    Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
    PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
    McLellan JS; Pancera M; Carrico C; Gorman J; Julien JP; Khayat R; Louder R; Pejchal R; Sastry M; Dai K; O'Dell S; Patel N; Shahzad-ul-Hussan S; Yang Y; Zhang B; Zhou T; Zhu J; Boyington JC; Chuang GY; Diwanji D; Georgiev I; Kwon YD; Lee D; Louder MK; Moquin S; Schmidt SD; Yang ZY; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Burton DR; Koff WC; Walker LM; Phogat S; Wyatt R; Orwenyo J; Wang LX; Arthos J; Bewley CA; Mascola JR; Nabel GJ; Schief WR; Ward AB; Wilson IA; Kwong PD
    Nature; 2011 Nov; 480(7377):336-43. PubMed ID: 22113616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic labeling of HIV-1 envelope glycoprotein gp120 to elucidate the effect of gp120 glycosylation on antigen uptake.
    Sun L; Ishihara M; Middleton DR; Tiemeyer M; Avci FY
    J Biol Chem; 2018 Sep; 293(39):15178-15194. PubMed ID: 30115684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction.
    Huang X; Jin W; Hu K; Luo S; Du T; Griffin GE; Shattock RJ; Hu Q
    Virology; 2012 Feb; 423(1):97-106. PubMed ID: 22192629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.
    Yang Q; Li C; Wei Y; Huang W; Wang LX
    Bioconjug Chem; 2010 May; 21(5):875-83. PubMed ID: 20369886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
    O'Rourke SM; Sutthent R; Phung P; Mesa KA; Frigon NL; To B; Horthongkham N; Limoli K; Wrin T; Berman PW
    PLoS One; 2015; 10(3):e0119608. PubMed ID: 25793890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
    Doores KJ; Burton DR
    J Virol; 2010 Oct; 84(20):10510-21. PubMed ID: 20686044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.